RT Journal Article
SR Electronic
T1 ACE2 Expression is Increased in the Lungs of Patients with Comorbidities Associated with Severe COVID-19
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.03.21.20040261
DO 10.1101/2020.03.21.20040261
A1 Pinto, Bruna G.G.
A1 Oliveira, Antonio E.R.
A1 Singh, Youvika
A1 Jimenez, Leandro
A1 Gonçalves, Andre N A.
A1 Ogava, Rodrigo L.T.
A1 Creighton, Rachel
A1 Schatzmann Peron, Jean Pierre
A1 Nakaya, Helder I.
YR 2020
UL http://medrxiv.org/content/early/2020/03/27/2020.03.21.20040261.abstract
AB The pandemic caused by the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS- CoV-2) has resulted in several thousand deaths worldwide in just a few months. Patients who died from Coronavirus disease 2019 (COVID-19) often had comorbidities, such as hypertension, diabetes, and chronic obstructive lung disease. The angiotensin-converting enzyme 2 (ACE2) was identified as a crucial factor that facilitates SARS-CoV2 to bind and enter host cells. To date, no study has assessed the ACE2 expression in the lungs of patients with these diseases. Here, we analyzed over 700 lung transcriptome samples of patients with comorbidities associated with severe COVID-19 and found that ACE2 was highly expressed in these patients, compared to control individuals. This finding suggests that patients with such comorbidities may have higher chances of developing severe COVID-19. We also found other genes, such as RAB1A, that can be important for SARS-CoV-2 infection in the lung. Correlation and network analyses revealed many potential regulators of ACE2 in the human lung, including genes related to histone modifications, such as HAT1, HDAC2, and KDM5B. In fact, epigenetic marks found in ACE2 locus were compatible to with those promoted by KDM5B. Our systems biology approach offers a possible explanation for increase of COVID-19 severity in patients with certain comorbidities.Competing Interest StatementThe authors have declared no competing interest.Funding StatementHIN is supported by CNPq (313662/2017-7) and the Sáo Paulo Research Foundation (FAPESP; grants 2017/50137-3, 2012/19278-6, 2018/14933-2, 2018/21934-5 and 2013/08216-2). RC was supported by an NSF Graduate Research Fellowship (DGE-1256082), NSF Graduate Research Opportunities Worldwide Fellowship, and by the STD & AIDS Research Training Fellowship Program (NIH 2T32AI007140-41).Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data can be found in Table S1.